Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer

Objective: Osteopontin (OPN), a phosphorylated sialoprotein, has been shown to overex-press in a variety of cancers and to contribute tumor progression and metastasis by increasing cell migration and adhesion. In the current study, we aimed to investigate the prognostic and predictive role of OPN in patients with advanced gastric cancer. Methods: A total of 42 consecutive chemonaive patients with advanced gastric cancer and 29 healthy controls were included. The patients were treated with a modified DCF regimen. The blood samples were obtained before each chemotherapy cycle from the patients and once from healthy controls. The plasma OPN is measured by ELISA. Results: The overall response and disease stabilization rates were 25% and 72%, respectively. The median serum OPN level of the patient group was significantly higher compared to healthy con-trols (176.9 ng/ml (range: 41.5-521.4) vs 64.3 ng/ml (range 42.1-105.3 ng/ml), p < 0.0001). The me-dian overall survival time was 7.0 +/- 1.1 (95% CI: 4.9-9.2) months and 1-year overall survival rate was 20.8%. The patients who responded to mDCF had lower plasma OPN levels than the non-re-sponding ones (110.7 +/- 29.3 ng/mL, 211.9 +/- 24.4 ng/mL respectively, p=0.002). The performance sta-tus and the plasma OPN levels were found to be significant factors for overall survival in the multi-variate analysis (p=0.004 and 0.016, respectively). Conclusion: The serum OPN seems to be a novel significant prognostic and predictive factor in pa-tients with advanced gastric cancer who were treated with DCF regimen.

Automated summary

The study indicates that higher serum OPN levels are associated with shorter survival time in patients with advanced gastric cancer. Patients who respond to DCF treatment have lower plasma OPN levels, with performance status and plasma OPN levels being significant factors in overall survival.